On November 15, 2018 bluebird bio, Inc. (Nasdaq: BLUE) reported that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston (Press release, bluebird bio, NOV 15, 2018, View Source [SID1234531365]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of bluebird bio’s presentation, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at View Source A replay of the webcast will be available on the bluebird bio website for 90 days following the conferences.

On November 15, 2018 INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the patient’s innate immune system, reported that Lazar Vujanovic, Ph.D., a research instructor at the University of Pittsburgh, presented results from a preliminary study at the 33rd annual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) meeting on November 9 (Press release, INmune Bio, NOV 15, 2018, View Source [SID1234531521]). The results of the research conducted at the University of Pittsburgh, demonstrated the potential effectiveness of INB03TM, the company’s lead drug candidate in treatment of drug-resistant melanoma, which was developed from patented intellectual property licensed from the University of Pittsburgh.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The study’s findings indicate a potential shift in approach to how clinicians may treat patients who harbor treatment-resistant cutaneous melanomas by using TNF receptors as biomarkers," said Dr. Vujanovic. "These results, showing the effectiveness of biomarker-guided soluble TNF-targeting strategy, are an encouraging development in potentially raising the standard of care for patients with treatment-resistant melanoma, which kills thousands each year."

Soluble TNF (sTNF) is an immunologic protein that has multiple functions in the development of cutaneous melanoma, the deadliest form of skin cancer. In a cohort of patients, sTNF facilitates tumor growth and drug resistance. Dr. Vujanovic’s data shows that sTNF may induce drug resistance and suggests that some melanoma patients may benefit from neutralization of sTNF with a drug like INB03. As an innate immunotherapy drug currently in Phase I trials, INB03 is being used in patients to neutralizes sTNF using a novel Dominant-Negative TNF technology.

"At INmune Bio we believe that, when possible, a patient’s cancer therapy should be guided by biomarkers that can better predict a favorable response to therapy," said INmune Bio co-founder and CEO, Raymond J. Tesi, M.D. "Dr. Vujanovic’s work is an example of how laboratory studies are the foundation of important concepts that can alter the treatment of cancer patients."

SITC is one of the leading organizations for the exchanging of ideas and discovery in the cancer immunotherapy field.

On November 15, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, reported that management will participate at both the Bryan, Garnier & Co 6th European Healthcare Conference and the Piper Jaffray 30th Annual Healthcare Conference (Press release, Celyad, NOV 15, 2018, View Source [SID1234532509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bryan, Garnier & Co 6th European Healthcare Conference will take place in Paris, France, on November 22-23, 2018. The Company will participate in investor meetings at the Conference.

The Piper Jaffray 30th Annual Healthcare Conference will take place in New York, NY on November 27-29, 2018 and the Company is scheduled to participate in a fireside chat on Tuesday, November 27 at 11:30 am Eastern Time. A live webcast of the discussion can be accessed here. An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.

On November 15, 2018 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported a presentation describing use of the Company’s proprietary Discovery Engine, featuring the Company’s Immune Repertoire Capture (IRC) technology, to characterize active B cell immune responses in nearly 200 cancer patients and to identify more than 1,000 tumor-targeting antibodies that bind to "public" tumor antigens (Press release, Atreca, NOV 15, 2018, View Source [SID1234531366]). The presentation, entitled "Identification of Functional Antitumor Antibodies from Immunoglobulin Sequence Repertoires of Cancer Patients," will be delivered by Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, on Friday, November 16, 2018 at 1:05 p.m. Western European Time at the 10th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place at the Lisbon Congress Center in Lisbon, Portugal, November 12-16, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our unique discovery platform enables us to identify, in an industrialized manner, functional antibodies generated by the active immune responses of cancer patients responding to therapy," said Tito A. Serafini, Ph.D., Chief Strategy Officer and an Atreca founder. "The results presented at this conference describe analyses of such antibodies from nearly 200 patients, including the identification of more than 1,000 patient antibodies that target non-autologous tumor selectively across multiple tumor types by binding to public antigens. We are using this library of tumor-targeting antibodies to develop therapeutics designed to treat large patient groups, while continuing to discover additional antibodies to add to our library. Our first program to emerge from our platform, ATRC-101, is anticipated to enter clinical development in 2019."

On November 14, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018, at 1:50pm ET at the Lotte New York Palace in New York City (Press release, ArQule, NOV 14, 2018, View Source [SID1234531291]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of the presentation will be available via the "Investors & Media" section of ArQule’s website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.